EU accepts GSK marketing application for kidney treatment
1st Mar 2022 07:01
(Sharecast News) - GlaxoSmithKline said the European Medicines Agency has accepted a marketing authorisation application (MAA) for its daprodustat treatment of chronic kidney disease (CKD).
Read moreGSK to spin off consumer healthcare unit in July
28th Feb 2022 11:37
(Sharecast News) - GlaxoSmithKline confirmed on Monday plans to float its consumer healthcare business this summer, just weeks after rebuffing a £50bn approach from Unilever.
Read moreGlaxo halts trial of respiratory virus maternal vaccine candidate
28th Feb 2022 07:50
(Sharecast News) - GlaxoSmithKline said on Monday that it had halted enrolment and vaccination in three trials being carried out to evaluate its respiratory syncytial virus (RSV) vaccine candidate in pregnant women.
Read moreGSK and Sanofi seek approval for Covid-19 jab
23rd Feb 2022 11:23
(Sharecast News) - GlaxoSmithKline and Sanofi are to seek regulatory approval for their Covid-19 vaccine candidate following successful efficacy trials.
Read moreGlaxo pauses enrolment and vaccination in RSV vaccine candidate trials
18th Feb 2022 07:37
(Sharecast News) - Drugmaker GlaxoSmithKline has voluntarily paused enrolment and vaccination in the GRACE phase III trial evaluating its potential respiratory syncytial virus maternal vaccine candidate, as well as two other trials of the candidate in pregnant women.
Read moreDirector dealings: GSK execs sell shares for tax bills, Airtel director makes £50k purchase
17th Feb 2022 16:06
(Sharecast News) - GlaxoSmithKline disclosed a number of executive awards on Thursday, with two of its directors making large sales to cover their tax bills.
Read moreGlaxo's Benlysta lupus treatment approved in China for adults
10th Feb 2022 09:42
(Sharecast News) - GlaxoSmithKline said on Thursday that Benlysta (belimumab) has been approved in China for the treatment of adult patients with active lupus nephritis (LN) who are receiving standard of care.
Read moreGSK Covid sales soar but sees slowdown next year
9th Feb 2022 08:29
(Sharecast News) - UK pharmaceutical giant GSK said Covid-related sales hit £1.4bn last year as it reported better-than-expected fourth-quarter earnings.
Read moreWednesday preview: Fedspeak, GSK in the spotlight
8th Feb 2022 15:00
(Sharecast News) - Inverstors' attention on Wednesday will be on appearances by two top US central bank officials, whose words will be carefully parsed for any policy relevant remarks.
Read moreGlaxo's ViiV Healthcare settles patent row with Gilead
2nd Feb 2022 07:54
(Sharecast News) - Specialist HIV company Viiv Healthcare - which is majority-owned by GlaxoSmithKline with Pfizer and Japan's Shionogi as shareholders - has settled a global patent infringement litigation with Gilead Sciences.
Read moreGlaxo's ViiV Healthcare gets FDA approval for HIV treatment
1st Feb 2022 15:05
(Sharecast News) - The US Food and Drug Administration has approved ViiV Healthcare's Cabenuva (cabotegravir, rilpivirine) for the treatment of HIV-1 in virologically-suppressed adults.
Read moreUnilever said to be planning layoffs after activist investor takes stake
25th Jan 2022 08:07
(Sharecast News) - Unilever is reportedly planning to slash several thousand management positions.
Read moreUnilever won't lift £50bn offer for GSK consumer health arm
19th Jan 2022 16:45
(Sharecast News) - Unilever will not be increasing its offer for GlaxoSmithKline's consumer healthcare business.
Read moreGSK chief science officer leaves to join US startup
19th Jan 2022 09:02
(Sharecast News) - GlaxoSmithKline said it had appointed Tony Wood as chief scientific officer designate after Hall Barron said he was resigning the post to run a new privately owned start-up biotech company. .
Read moreBoA stays 'neutral' on Unilever, says upside and downside risks 'well balanced'
17th Jan 2022 13:15
(Sharecast News) - Analysts at Bank of America reiterated their 'neutral' recommendation for shares of Unilever following news at the weekend that it had made three bids for GlaxoSmithKline's consumer health business, telling clients they belived that upside and downside risks to the share price were "well balanced" at current levels.
Read more